Evacetrapib

Generic Name
Evacetrapib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C31H36F6N6O2
CAS Number
1186486-62-3
Unique Ingredient Identifier
51XWV9K850
Background

Evacetrapib has been used in trials studying the basic science and treatment of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hepatic Insufficiency, and Cardiovascular Disease.

Associated Conditions
-
Associated Therapies
-

A Study of Different Particle Sizes of Evacetrapib in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-07-14
Last Posted Date
2018-12-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
95
Registration Number
NCT02497391
Locations
🇸🇬

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-02-19
Last Posted Date
2018-10-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
34
Registration Number
NCT02365558
Locations
🇺🇸

Covance Madison, Madison, Wisconsin, United States

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2014-10-09
Last Posted Date
2018-10-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
54
Registration Number
NCT02260635
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

First Posted Date
2014-10-09
Last Posted Date
2018-10-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
149
Registration Number
NCT02260648
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

First Posted Date
2014-08-28
Last Posted Date
2019-10-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
366
Registration Number
NCT02227784
Locations
🇺🇸

Alan Graff, MD, PA, Fort Lauderdale, Florida, United States

🇺🇸

Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States

🇺🇸

Maryland Cardiovascular Specialists, Baltimore, Maryland, United States

and more 60 locations

A Study of Evacetrapib in Healthy Japanese Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-08-27
Last Posted Date
2018-11-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
48
Registration Number
NCT02226653
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan

A Study of Evacetrapib in Participants With Abnormal Cholesterol

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-06-20
Last Posted Date
2018-10-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
101
Registration Number
NCT02168803
Locations
🇺🇸

Covance, Dallas, Texas, United States

🇺🇸

Covance Clinical Research Inc, Madison, Wisconsin, United States

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-06-12
Last Posted Date
2018-10-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
24
Registration Number
NCT02161731
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

First Posted Date
2014-06-05
Last Posted Date
2018-10-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
62
Registration Number
NCT02156492
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China

A Study of Evacetrapib in Japanese and Non-Japanese Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-10-09
Last Posted Date
2018-10-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
24
Registration Number
NCT01958489
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath